FAQ on HIV Management

Top 3 FAQs on HIV Management

Miranda Manier, BA
10/02/2025

Managing HIV today means balancing speed, precision, and prevention. From deciding when to start antiretroviral therapy (ART) to optimizing follow-up labs and ensuring vaccine and prophylaxis coverage, clinicians are faced with decisions that directly impact outcomes. These three questions—and their evidence-based answers—represent the most practical, high-yield updates in HIV management for specialists today.

How quickly should I start ART after a new diagnosis?

Immediately—ideally the same day, after drawing baseline labs.

Rapid start shortens time to suppression and improves outcomes; choose a high-barrier INSTI-based regimen and adjust if resistance or HBV coinfection requires.1,2 Start same day in primary care after drawing baseline labs; do not delay for specialist scheduling.3

References

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Initiation of antiretroviral therapy in adults and adolescents with HIV. Accessed August 13, 2025. https://clinicalinfo.hiv-stage.od.nih.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/initiation-antiretroviral-therapy-adult-adolescent-arv.pdf
  2. Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society–USA panel. JAMA. 2025;333(7):609-628. doi:10.1001/jama.2024.24543
  3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated September 12, 2024. Accessed August 13, 2025. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
What monitoring cadence should I use once ART is started?

Check HIV RNA at 4–6 weeks, repeat every 1–3 months until suppressed, then every 3–6 months (q6 months may be reasonable after ≥2 years of stable suppression).

Use less than 200 copies/mL as the clinical definition of viral suppression and reinforce U=U for patients with sustained suppression. Optimal suppression is a confirmed HIV RNA below the assay’s lower limit of detection (often <20 copies/mL).1,2

References

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated September 12, 2024. Accessed August 13, 2025. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Laboratory tests for initial assessment and follow-up. Accessed August 13, 2025. https://clinicalinfo.hiv-stage.od.nih.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/tests-initial-assessment-and-follow-full
Which vaccines and OI prophylaxis matter most?

Give PCV20 or PCV21 (or PCV15→PPSV23), influenza annually, HepA/HepB, HPV, and others per ACIP. 

Avoid live vaccines if CD4 is less than 200. Start PCP prophylaxis at CD4 < 200 and Toxoplasma prophylaxis at CD4 is less than 100 if IgG-positive; do not give MAC prophylaxis if ART is initiated promptly. Reassess as CD4 recovers.1,2

References

  1. Spach DH. Opportunistic infections: prevention. National HIV Curriculum (University of Washington). Last updated February 3, 2025. Accessed August 13, 2025. https://www.hiv.uw.edu/pdf/co-occurring-conditions/opportunistic-infections-prevention/core-concept/all
  2. Centers for Disease Control and Prevention. Recommended immunization schedule for adults aged 19 years or older—United States, 2025. Accessed August 13, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/adult/adult-combined-schedule.pdf
Return to top